Actavis has sold a product portfolio of 7 established brands to Glenmark Pharmaceuticals Ltd. for an undisclosed sum. The agreement with Glenmark is effective from 1 July 2008.

The divestment of the Actavis and Biovena products is part of Actavis‘ ongoing integration process, following the group‘s acquisition of more than 20 companies in recent years.

The largest products in the portfolio sold to Glenmark are Cital, the leading brand of the anti-depressant citalopram in Poland, and Lamotrix (lamotrigine), a leading treatment for the management of epilepsy.